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Metformin and the risk of renal cell carcinoma: a case–control
analysis
Claudia Beckera, Susan S. Jickc, Christoph R. Meiera,b,c and Michael Bodmera
Metformin use has been associated previously with a
decreased risk of cancer, but its association with renal cell
carcinoma has not yet been investigated in observational
studies. We aimed to explore the association between the
use of metformin and other antidiabetic drugs and the risk
of renal cell carcinoma (RCC). We carried out a case–control
analysis in the UK-based Clinical Practice Research
Datalink. We included individuals with an incident RCC
between January 1995 and December 2013 younger than
the age of 90 years. Six controls per case were matched on
age, sex, calendar time, general practice, and number of
years of active history in the Clinical Practice Research
Datalink before the index date. We included BMI, smoking,
alcohol consumption, hypertension, and diabetes mellitus
as potential confounders in a multivariate model using
conditional logistic regression to calculate odds ratios with
95% confidence intervals, and we carried out a sensitivity
analysis restricted only to diabetic cases and controls. Long-
term use of metformin was not associated with an altered
relative risk of RCC (≥30 prescriptions, adjusted odds ratio
1.18, 95% confidence interval 0.88–1.58), nor was use of
other antidiabetic drugs. Results in the sensitivity analysis
including only diabetic cases and controls were largely the
same. Use of metformin or other antidiabetic drugs was not
associated with a materially altered risk of RCC. Further
studies are warranted. European Journal of Cancer
Prevention 26:257–262 Copyright © 2017 Wolters Kluwer
Health, Inc. All rights reserved.
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Introduction
More than 300 000 new cases of kidney cancer were
diagnosed in 2012 worldwide (Ferlay et al., 2015). The age-
standardized incidence rates in 2012/100 000 person-years
were 12.6 in men and 6.2 in women in more developed
areas and 3.4 in men and 1.8 in women in less developed
areas of the world (Torre et al., 2015). Renal cell carcinoma
(RCC) is more common in men than in women (Ferlay
et al., 2015). Furthermore, the incidence of RCC has almost
doubled (from 7.6 in 1988 to 11.7/100 000 person-years in
2006) in North America (Sun et al., 2011). The 5-year
survival rate for RCC is 5–80% depending on the stage at
cancer diagnosis (Cancer Research UK, 2015). RCC, the
most frequent renal malignancy, includes several histolo-
gical cell types; the most common subtype (70%) is clear
cell RCC (Ljungberg et al., 2011).
Known risk factors for RCC are cigarette smoking (Hunt
et al., 2005), obesity (Pischon et al., 2006; Adams et al.,
2008; Renehan et al., 2008), and hypertension (Chow
et al., 2000; Vatten et al., 2007). Alcohol consumption has
repeatedly been associated with a decreased risk of RCC
(Bellocco et al., 2012; Song et al., 2012).
Patients with urinary tract infections (Parker et al., 2004),
end-stage renal disease (Farivar-Mohseni et al., 2006),
cystic kidney disease (Denton et al., 2002), or kidney
transplantation (Kasiske et al., 2004) have been shown to
have an increased risk for RCC. NSAIDs including
acetylsalicylic acid (ASA) have been associated with an
increased risk of cancer in one study (Cho et al., 2011),
whereas other studies have not reported such an associa-
tion (Tavani et al., 2010; Liu et al., 2013b). Oral contra-
ceptives (OC) have previously been found to protect
against RCC in women (Kabat et al., 2007), whereas the
effect of exposure to hormone replacement therapy
(HRT) is not clear (Molokwu et al., 2007; Lee et al., 2009).
There is no agreement on whether type 2 diabetes mel-
litus is causally associated with the risk of RCC or whe-
ther the association is confounded by obesity (Lindblad
et al., 1999; Larsson and Wolk, 2011).
In recent years, considerable research has been devoted
to studying the association between metformin and var-
ious cancer entities (Decensi et al., 2010; Noto et al., 2012;
Franciosi et al., 2013). Metformin is believed to have
anticancer properties on the basis of two different
mechanisms. First, metformin decreases insulin resis-
tance [insulin resistance has been associated with an
increased risk of several cancer types, such as breast,
colon, and pancreatic cancer (Lipscombe et al., 2006;
Frasca et al., 2008; Hernandez-Diaz and Adami, 2010)]
and it also lowers circulating insulin levels [insulin has
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mitogenic properties (Frasca et al., 2008)]. Second, met-
formin acts as a growth inhibitor. It has been shown that
this growth inhibition, at least in part, is mediated by
upregulation of AMP-activated protein kinase activity
and downstream suppression of signaling through the
mammalian target of rapamycin (mTOR).
In RCC pathogenesis, mTOR inhibition has been shown
to play a central role in the suppression of tumor growth
(Hager et al., 2009; Keefe et al., 2013). Thus, temsir-
olimus, an mTOR-inhibitor, has been approved for the
treatment of metastatic RCC (Hudes et al., 2007).
Metformin has also been shown to inhibit mTOR sig-
naling in RCC cells in vitro, as well as to inhibit RCC
tumor growth in a xenograft model (Liu et al., 2013a).
To the best of our knowledge, no observational study has
as yet evaluated the effect of antidiabetic drug use on the
risk of renal carcinoma. We therefore carried out a
case–control analysis using the UK-based Clinical
Practice Research Datalink (CPRD) to explore whether
the use of metformin or other antidiabetic drugs alters the
risk of developing RCC.
Methods
Data source
We carried out a retrospective case–control analysis using
data from the CPRD (Williams et al., 2012). The CPRD
provides health care information on some eight million
patients in the UK and has been previously described in
detail (Walley and Mantgani, 1997; Williams et al., 2012).
General practitioners record information on demographics,
diagnoses, and drug prescriptions as well as on patient
referrals and hospital admissions using standardized coding
systems. The general practitioners generate prescriptions
directly with the computer and this information is auto-
matically transcribed into the individual computerized
patient records. In addition, the CPRD records information
on BMI and the lifestyle variables alcohol consumption
and smoking. Recorded information on drug exposure and
diagnoses has been validated repeatedly and proven to be
of high quality (Jick et al., 2003; Herrett et al., 2010). The
CPRD currently covers about 7% of the UK population
and enrolled patients are representative of the UK with
respect to age, sex, and geographic distribution (Lawrenson
et al., 1999). The CPRD is managed by the Medicines and
Healthcare products Regulatory Agency in the UK. The
study protocol was reviewed and approved by the
Independent Scientific Advisory Committee for Medicines
and Healthcare products Regulatory Agency database
research (reference number 14_175) and made available to
the journal reviewers. The investigators had access to
anonymous information only.
Study population
We defined as cases all individuals in the base population
younger than the age of 90 years between January 1995
and December 2013 who had an incident diagnosis of
RCC in their record. We excluded all patients with a
recorded diagnosis of HIV, alcoholism, or any malig-
nancy, as well as those with less than 3 years of medical
history in the CPRD computer record before the diag-
nosis date. We shifted the diagnosis date backwards in
time by 2 years to account for cancer latency and to
ensure that potential exposure to antidiabetic drugs
occurred before cancer onset. The subsequently used
term ‘index date’ will refer to the shifted diagnosis date.
To minimize case misclassification, we identified codes
(subsequently referred to as supporting codes) that pro-
vided reassurance that the cancer diagnosis was valid,
such as codes for cancer-related surgery, radiotherapy,
chemotherapy, antiangiogenic therapy, immunotherapy,
targeted therapy, or other oncology-specific codes recor-
ded within 1 year before or after the first recorded RCC
diagnosis.
Up to six controls (individuals with no evidence for RCC)
were matched to each case on calendar time (same index
date), age, sex, general practice, and number of years of
active history in the CPRD before the diagnosis date. We
applied the same exclusion criteria to controls as to cases.
Exposure to metformin or other antidiabetic agents
We identified prescriptions for insulin and/or for oral
antidiabetic drugs (metformin, sulfonylureas, thiazolidi-
nediones, megltinides, dipeptidyl peptidase-4 inhibitors,
incretin-mimetics, and glucosidase inhibitors) docu-
mented in the computer records before the index date.
We classified patients by type of antidiabetic treatment
and defined the extent of exposure according to the
recorded number of prescriptions before the index date
(short-term 1–29, or long-term use≥ 30 prescriptions).
Exposure to meglitinides, dipeptidyl peptidase-4 inhibi-
tors, incretin-mimetics, and glucosidase inhibitors was
low and we therefore could not include these drugs in the
final multivariate model. We compared the use of each
antidiabetic drug with nonuse of that drug and adjusted
for sequential or concurrent use of other antidiabetic
drugs in the multivariate models.
Statistical analysis
We carried out conditional logistic regression analyses
using SAS Statistical Software, version 9.4 (SAS Institute
Inc., Cary, North Carolina, USA) to calculate relative risk
estimates as odds ratios (OR) with 95% confidence
intervals (CIs). We controlled for the previously men-
tioned matching variables as well as for smoking status
(never, exsmoker, current, or unknown), BMI (< 25,
25–29.9, ≥ 30 kg/m2, or unknown), alcohol consumption
(never, current, past, or unknown), and the comorbidities
hypertension and diabetes mellitus in the multivariate
model. We included these confounders on the basis of
previous clinical knowledge. In addition, we explored the
association between various potential confounders and
the risk of RCC in univariate analyses including recorded
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urinary tract infections, renal failure, renal transplanta-
tion, polycystic kidney disease, and other comorbidities
such as congestive heart failure, ischemic heart disease,
stroke, dyslipidemia, previous A1c levels, as well as drug
therapy with ASA, NSAIDs, OCs, or HRT. However, as
these variables did not alter the risk estimate by more
than 10%, we decided not to include them in the final
multivariate model.
We then carried out a sensitivity analysis restricted to
cases with at least one supporting code and their matched
controls.
Diabetes mellitus has been shown to be associated with an
increased risk of cancer in some previous studies. We
therefore carried out an additional analysis restricted to
cases with diabetes and newly matched controls who also
had diabetes. In this sensitivity analysis, we additionally
adjusted for diabetes duration. Diabetes duration was
defined as the time from the date of a first recorded
diagnosis of diabetes to the index date. In addition, we
explored whether cases with long-term metformin use
(≥30 prescriptions) had a longer duration of diabetes mel-
litus than controls and therefore had more opportunity to
receive prescriptions. This was done to address potential
exposure opportunity bias.
Results
We identified a total of 3506 cases with incident RCC and
21 038 matched controls between January 1995 and
December 2013. Almost 60% of the cases were men. The
mean (±SD) age of the cases and controls at the index date
was 65.0 (±12.8) years. The mean duration of medical history
recorded in the CPRD before the cancer diagnosis was 11.2
(±4.8) years. Eighty percent of the cases had either radio-
therapy, chemotherapy, an oncology code, RCC-related sur-
gery or antiangiogenic, immunotherapy, or targeted therapy
documented in their record within 1 year of the index date.
The main characteristics of the cases and controls are
shown in Table 1. Having a history of cystic kidney dis-
ease or of renal transplant was each associated with a
strong risk of RCC: ORs 2.53 (95% CI 1.2–5.33) and 3.30
(95% CI 1.5–7.24), respectively. Current smokers com-
pared with nonsmokers, and obese compared with normal
weight patients were at a slightly increased risk of
developing RCC. Alcohol use was not materially asso-
ciated with the risk of RCC, nor was use of ASA, NSAIDs,
OCs, and HRT (Table 1). Hypertension was associated
with a slightly increased risk of RCC. Diabetes mellitus
was also associated with a slightly increased OR for RCC;
however, we did not observe a trend toward an increased
risk with longer diabetes duration (test for trend: P= 0.25)
and increased A1c levels were not associated with RCC.
Table 1 Characteristics of renal cell carcinoma cases and controls
Cases [n (%)]
(n=3506)
Controls [n (%)]
(n=21 038) Crude OR (95% CI)
Age (years)
<40 126 (3.6) 758 (3.6) –
40–49 297 (8.5) 1770 (8.4) –
50–59 651 (18.6) 3944 (18.8) –
60–69 991 (28.3) 5999 (28.5) –
70–79 1034 (29.5) 6128 (29.1) –
≥80 407 (11.6) 2439 (11.6) –
Sex
Male 2099 (59.9) 12 594 (59.9) –
Female 1407 (40.1) 8444 (40.1) –
Smoking
Nonsmoker 1459 (41.6) 9742 (46.3) 1.00 (Referent)
Current 711 (20.3) 3361 (16.0) 1.43 (1.30–1.58)
Past 1058 (30.2) 6220 (29.6) 1.14 (1.05–1.25)
Unknown 278 (7.9) 1715 (8.2) 1.08 (0.93–1.26)
BMI
<25 917 (26.2) 6505 (30.9) 1.00 (Referent)
25–29.9 1174 (33.5) 7221 (34.3) 1.16 (1.06–1.27)
≥30 823 (23.5) 3675 (17.5) 1.61 (1.45–1.79)
Unknown 592 (16.9) 3637 (17.3) 1.15 (1.02–1.29)
Alcohol use
Never 617 (17.6) 3301 (15.7) 1.00 (Referent)
Current 2442 (69.7) 14 843 (70.6) 0.87 (0.79–0.96)
Past 59 (1.7) 309 (1.5) 1.02 (0.76–1.37)
Unknown 388 (11.1) 2585 (12.3) 0.78 (0.67–0.90)
Comorbiditiesa
CHF 117 (3.3) 619 (2.9) 1.15 (0.93–1.41)
IHD 494 (14.1) 2742 (13.0) 1.11 (0.99–1.23)
Hypertension 1464 (41.8) 7130 (33.9) 1.43 (1.37–1.60)
Stroke/TIA 231 (6.6) 1223 (5.8) 1.15 (0.99–1.33)
Dyslipidemia 501 (14.3) 2637(12.5) 1.19 (1.06–1.32)
Diabetes mellitus 394 (11.2) 1972 (9.4) 1.23 (1.10–1.39)
DM duration
<4 yearsb
117 (33.2) 729 (34.5) 1.00 (Referent)
DM duration
4–9 yearsb
128 (36.4) 780 (36.9) 1.03 (0.78–1.35)
DM duration
≥10 yearsb
107 (30.4) 605 (28.6) 1.11 (0.83–1.47)
A1c <53 mmol/l
(7%)b
137 (38.9) 781 (36.9) 1.00 (Referent)
A1c≥53 mmol/l
(7%)b
156 (44.3) 940 (44.5) 0.94 (0.73–1.21)
Unknown A1c levelb 59 (16.8) 393 (18.6) 0.82 (0.56–1.19)
UTI 527 (15.0) 2718 (12.9) 1.22 (1.10–1.36)
ESRD 26 (0.7) 101 (0.5) 1.55 (1.01–2.39)
Cystic kidney disease 10 (0.3) 24 (0.1) 2.53 (1.20–5.33)
Renal transplantation 10 (0.3) 19 (0.1) 3.30 (1.50–7.24)
NSAIDs
No previous use 1300 (37.1) 8157 (38.8) 1.00 (Referent)
1–2 Rx 880 (25.1) 5230 (24.9) 1.06 (0.97–1.17)
3–9 Rx 695 (19.8) 4264 (20.3) 1.04 (0.93–1.15)
≥10 Rx 631 (18.0) 3387 (16.1) 1.19 (1.07–1.33)
ASA
No prior use 2534 (72.3) 15 598 (74.1) 1.00 (Referent)
1–14 Rx 411 (11.7) 2255 (10.7) 1.14 (1.01–1.28)
≥15 Rx 561 (16.0) 3185 (15.1) 1.11 (0.99–1.23)
Oral contraceptives (women only)
No previous use 1321 (93.9) 7819 (93.3) 1.00 (Referent)
Any use 86 (6.1) 565 (6.7) 0.82 (0.59–1.15)
HRT (women only)
No previous use 1074 (76.3) 6341 (75.1) 1.00 (Referent)
1–9 Rx 169 (12.0) 973 (11.5) 1.00 (0.83–1.21)
≥10 Rx 164 (11.7) 1130 (13.4) 0.83 (0.68–1.01)
A1c, glycated hemoglobin (assessed for diabetics only, ‘unknown’ level includes
recordings earlier than 1 year before the cancer diagnosis); ASA, acetylsalicylic
acid; CHF, congestive heart failure; CI, confidence interval; DM, diabetes mellitus;
ESRD, end-stage renal disease; HRT, hormone replacement therapy; IHD,
ischemic heart disease; OR, odds ratio; Rx, prescriptions; TIA, transient ischemic
attack; UTI, urinary tract infection
aReference category for comorbidities is ‘no recorded diagnosis for the respective
disease’.
bAnalysis restricted to cases and controls with a recorded diagnosis of diabetes
mellitus.
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Long-term use of metformin (≥30 prescriptions) was not
associated with a statistically significantly decreased risk
of RCC in either the main analysis (adjusted OR 1.18,
95% CI 0.88–1.58) or in the analysis restricted to diabetic
patients (adjusted OR 0.91, 95% CI 0.64–1.29) (Tables 2
and 3). The sensitivity analysis restricted to cases with
recorded cancer treatment yielded results very similar to
the main analysis (adjusted OR 1.12, 95% CI 0.81–1.57
for RCC in association with the long-term use of met-
formin). Diabetes duration was similar in cases and con-
trols: among all long-term metformin users, 97% of the
cases had diabetes for more than 4 years and 51% for
more than 10 years. Similarly, 94% of the controls had
more than a 4-year history of diabetes and 50% had more
than a 10-year history of diabetes. Use of sulfonylureas,
insulin, or thiazolidinediones was not associated with a
statistically significant altered risk of RCC in the main
analysis or in the various sensitivity analyses (Tables 2
and 3).
Discussion
In this large case–control analysis, metformin exposure
was not associated with an altered risk for RCC. To the
best of our knowledge, no other observational study has
analyzed this association in detail. Results of in-vitro and
in-vivo experiments have suggested a possible protective
effect of metformin on the development of RCC (Liu
et al., 2013b). However, a cohort study from the USA on
the risk of cancer after pioglitazone exposure also ana-
lyzed ever versus never use of metformin and found an
increased risk for cancers of the kidney and the renal
pelvis (Ferrara et al., 2011). Furthermore, the results of
two US-based retrospective studies did not find protec-
tive effects of metformin administered before RCC-
related surgery on disease progression or RCC mortality
(Hakimi et al., 2013; Psutka et al., 2014). Metformin has
been associated with alterations in cancer risk for several,
but not for all types of cancer, in numerous observational
studies; despite these intriguing findings, only rando-
mized trials can ultimately answer the question of
whether metformin is indeed causally linked to a reduced
cancer risk for certain cancer types (Gandini et al., 2014).
Our results are consistent with previous studies reporting
an increased risk of RCC in smokers (Hunt et al., 2005)
and in obese individuals (Pischon et al., 2006; Adams
et al., 2008; Renehan et al., 2008), as well as a reduced risk
of RCC associated with alcohol consumption (Lee et al.,
2007; Bellocco et al., 2012; Song et al., 2012) and OC
exposure (Kabat et al., 2007). In addition, we also
observed a marginal but statistically significantly
increased risk of RCC in association with diabetes.
However, the association was independent of diabetes
duration, making a causal association questionable.
Our study has several limitations: the date on which the
cancer diagnosis was recorded most likely does not cor-
respond to the actual onset of the disease. It is impossible
to establish the precise date of cancer onset in any given
patient. By shifting the index date 2 years backwards in
time, we increased the likelihood that the index date was
closer to disease onset and that potential exposure to
antidiabetic drugs preceded the development of RCC. In
addition, misclassification of RCC cases may be present
to some degree in any observational study. We therefore
identified documented cancer therapies or oncologic
interventions to validate the recorded cancer diagnoses;
80% of the cancer cases had at least one such recording
within 1 year of the index date, providing evidence that
the degree of misclassification is small. In the CPRD,
cancer diagnoses have been shown to be generally of
high validity (Boggon et al., 2013). Our sensitivity ana-
lysis, which was restricted to cases with a high likelihood
of a valid RCC diagnosis, yielded results very similar to
the main analysis. We could incorporate many potential
confounders into our analysis, such as BMI, smoking, a
range of comorbid conditions, and prescriptions for other
drugs. However, residual confounding by, for example,
physical activity, diet, or socioeconomic status may still
exist to some degree as these parameters are not recorded
routinely in the CPRD. However, by matching cases and
Table 2 ORs for RCC for antidiabetic drugs in all cases and controls
Drugs and number of prescriptions Cases [n (%)] (n=3506) Controls [n (%)] (n=21 038) Crude OR (95% CI) Adjusted ORa (95% CI)
Metformin
No previous use 3260 (93.0) 19 879 (94.5) 1.00 (Referent) 1.00 (Referent)
Any use 246 (7.0) 1159 (5.5) 1.31 (1.13–1.51) 1.15 (0.90–1.46)
1–29 128 (3.7) 609 (2.9) 1.29 (1.06–1.57) 1.13 (0.86–1.48)
≥30 118 (3.4) 550 (2.6) 1.32 (1.08–1.62) 1.18 (0.88–1.58)
Sulfonylurea
No prior use 3320 (94.7) 20 072 (95.4) 1.00 (Referent) 1.00 (Referent)
Any use 186 (5.3) 966 (4.6) 1.17 (0.99–1.37) 0.91 (0.72–1.16)
Insulin
No previous use 3431 (97.9) 20 658 (98.2) 1.00 (Referent) 1.00 (Referent)
Any use 75 (2.1) 380 (1.8) 1.19 (0.93–1.53) 0.99 (0.75–1.31)
TZD
No previous use 3458 (98.6) 20 785 (98.8) 1.00 (Referent) 1.00 (Referent)
Any use 48 (1.4) 253 (1.2) 1.14 (0.84–1.56) 0.86 (0.61–1.22)
CI, confidence interval; OR, odds ratio; RCC, renal cell carcinoma; TZD, thiazolidinediones.
aAdjusted for all other medications in this table, BMI, smoking, alcohol consumption, hypertension, and diabetes mellitus.
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controls on general practice, we were at least in a position
to partially control for confounding by socioeconomic
status as patients from the same neighborhood are likely
to attend the same general practice. Another limitation of
our analysis is the number of unknown values for BMI.
However, in the sensitivity analysis restricted only to
diabetic patients, the percentage of missing values for
BMI was low (3.7%).
Our study has several strengths: the data source is a well-
established primary care database of high quality and
completeness. The information on drug exposure and
diagnoses was recorded prospectively and independent
of a study hypothesis; thus, recall bias could not have
influenced our results. Furthermore, by excluding all
patients with less than 3 years of recorded history in the
database before the index date, we minimized the risk of
including prevalent cancer cases. Also, time window bias
did likely not alter our findings as diabetes duration was
not meaningfully associated with an altered risk of RCC
and, in addition, cases and controls had a comparable
duration of diabetes history in each metformin exposure
category. Finally, our sensitivity analyses restricted to
cases and controls with diagnosed diabetes, or restricted
to cases with additional information supporting the
validity of the cancer diagnosis, all yielded similar results,
which further strengthen our results.
In conclusion, we did not find an altered relative risk of
RCC associated with exposure to antidiabetic drugs in
this large population-based study.
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Metformin and renal cell cancer Becker et al. 261
Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved.
Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ (2010). Validation and
validity of diagnoses in the General Practice Research Database: a
systematic review. Br J Clin Pharmacol 69:4–14.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. (2007).
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
N Engl J Med 356:2271–2281.
Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P (2005). Renal cell
carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J
Cancer 114:101–108.
Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodríguez LA, Ruigómez A,
Meier CR, et al. (2003). Validity of the general practice research database.
Pharmacotherapy 23:686–689.
Kabat GC, Silvera SA, Miller AB, Rohan TE (2007). A cohort study of reproductive
and hormonal factors and renal cell cancer risk in women. Br J Cancer
96:845–849.
Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004). Cancer after kidney
transplantation in the United States. Am J Transplant 4:905–913.
Keefe SM, Nathanson KL, Rathmell WK (2013). The molecular biology of renal
cell carcinoma. Semin Oncol 40:421–428.
Larsson SC, Wolk A (2011). Diabetes mellitus and incidence of kidney cancer: a
meta-analysis of cohort studies. Diabetologia 54:1013–1018.
Lawrenson R, Williams T, Farmer R (1999). Clinical information for research; the
use of general practice databases. J Public Health Med 21:299–304.
Lee JE, Hunter DJ, Spiegelman D, Adami HO, Albanes D, Bernstein L, et al.
(2007). Alcohol intake and renal cell cancer in a pooled analysis of 12 pro-
spective studies. J Natl Cancer Inst 99:801–810.
Lee JE, Hankinson SE, Cho E (2009). Reproductive factors and risk of renal cell
cancer: the Nurses’ Health Study. Am J Epidemiol 169:1243–1250.
Lindblad P, ChowWH, Chan J, Bergström A, Wolk A, Gridley G, et al. (1999). The
role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia
42:107–112.
Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE (2006). Increased
prevalence of prior breast cancer in women with newly diagnosed diabetes.
Breast Cancer Res Treat 98:303–309.
Liu J, Li M, Song B, Jia C, Zhang L, Bai X, Hu W (2013a). Metformin inhibits renal
cell carcinoma in vitro and in vivo xenograft. Urol Oncol 31:264–270.
Liu W, Park Y, Purdue MP, Giovannucci E, Cho E (2013b). A large cohort study of
nonsteroidal anti-inflammatory drugs and renal cell carcinoma incidence in the
National Institutes of Health-AARP Diet and Health Study. Cancer Causes
Control 24:1865–1873.
Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA
(2011). The epidemiology of renal cell carcinoma. Eur Urol 60:615–621.
Molokwu JC, Prizment AE, Folsom AR (2007). Reproductive characteristics and
risk of kidney cancer: Iowa Women’s Health Study. Maturitas 58:156–163.
Noto H, Goto A, Tsujimoto T, Noda M (2012). Cancer risk in diabetic patients
treated with metformin: a systematic review and meta-analysis. PLoS One 7:
e33411.
Parker AS, Cerhan JR, Lynch CF, Leibovich BC, Cantor KP (2004). History of
urinary tract infection and risk of renal cell carcinoma. Am J Epidemiol
159:42–48.
Pischon T, Lahmann PH, Boeing H, Tjønneland A, Halkjaer J, Overvad K, et al.
(2006). Body size and risk of renal cell carcinoma in the European
Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer
118:728–738.
Psutka SP, Boorjian SA, Lohse CM, Stewart SB, Tollefson MK, Cheville JC, et al.
(2014). The association between metformin use and oncologic outcomes
among surgically treated diabetic patients with localized renal cell carcinoma.
Urol Oncol [Epub ahead of print].
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008). Body-mass index
and incidence of cancer: a systematic review and meta-analysis of pro-
spective observational studies. Lancet 371:569–578.
Song DY, Song S, Song Y, Lee JE (2012). Alcohol intake and renal cell cancer
risk: a meta-analysis. Br J Cancer 106:1881–1890.
Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, et al. (2011).
Age-adjusted incidence, mortality, and survival rates of stage-specific renal
cell carcinoma in North America: a trend analysis. Eur Urol 59:135–141.
Tavani A, Scotti L, Bosetti C, Dal Maso L, Montella M, Ramazzotti V, et al. (2010).
Aspirin and risk of renal cell cancer in Italy. Eur J Cancer Prev 19:272–274.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015). Global
cancer statistics, 2012. CA Cancer J Clin 65:87–108.
Vatten LJ, Trichopoulos D, Holmen J, Nilsen TI (2007). Blood pressure and renal
cancer risk: the HUNT Study in Norway. Br J Cancer 97:112–114.
Walley T, Mantgani A (1997). The UK general practice research database. Lancet
350:1097–1099.
Williams T, van Staa T, Puri S, Eaton S (2012). Recent advances in the utility and
use of the general practice research database as an example of a UK Primary
Care Data resource. Ther Adv Drug Saf 3:89–99.
262 European Journal of Cancer Prevention 2017, Vol 26 No 3
Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved.
